Sapien 3 valve for younger Chinese patients with severe aortic stenosis
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests a newer artificial heart valve (Sapien 3) placed through a small tube in the leg, for younger people (50–70) with severe aortic stenosis. It aims to see if this less invasive option works well in this age group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 70 years old.
- You have severe aortic valve stenosis (the valve is narrowed and not working well).
- Your valve is a common shape (tricuspid or type-1 bicuspid) as seen on a CT scan.
- You do not need open-heart surgery for other heart problems.
- Your leg arteries are healthy enough for a catheter procedure.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to replace your narrowed aortic valve without open-heart surgery, using a device called SAPIEN 3. It is designed for people with a specific valve shape (Type 0 bicuspid) who have severe symptoms.
This trial compares a less invasive valve replacement (TAVR) with traditional open-heart surgery for people with a specific type of severe aortic valve narrowing (bicuspid valve). It aims to see which approach works better for those at intermediate or low surgical risk.
This trial compares two newer types of replacement heart valves (SAPIEN 3 Ultra Resilia and Evolut FX) to see which one works better for people with severe aortic stenosis, a condition where the heart's main valve becomes narrow. If you join, you'll be randomly assigned to receive one of the two valves during your TAVI procedure.
This trial compares two ways to replace a narrowed aortic heart valve in patients aged 65 to 75. It aims to find which approach—surgical valve replacement or a catheter-based procedure—works better for people in this age group.
This study follows patients with severe aortic stenosis who get a new heart valve (the SAPIEN 3 Ultra RESILIA) through a less invasive procedure (TAVR). Researchers want to see how well this valve works over time using special heart ultrasound tests.
This study compares regular monitoring (“clinical surveillance”) versus replacing the aortic valve using a minimally invasive procedure called TAVR for people with moderate aortic stenosis. It aims to see which approach better reduces symptoms or heart damage over time.
Hear when a new AORTIC VALVE DISEASES trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.